COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,015 Articles (22,627 medRxiv, 8,388 bioRxiv)

Most recent first Previous |  Page 2431: Articles 24301-24310  | Next

Evaluation of diversity levels in HIV-1 virus integrase gene sequences, supporting the lack of target specificity of ivermectin versus the integrase-importin complex in SARS-CoV-2 infection
Felix, P. T.
10.1101/2020.07.18.210096 — Posted: 2020-07-20
Population genetic analysis of Indian SARS-CoV-2 isolates reveals a unique phylogenetic cluster
Das, D., Akkipeddi, V. S. S. N. R.
10.1101/2020.07.19.197129 — Posted: 2020-07-20
SARS-CoV2 spike protein displays biologically significant similarities with paramyxovirus surface proteins; a bioinformatics study
Ahmadi, E., Zabihi, M. R., Hosseinzadeh, R., Noorbakhsh, F.
10.1101/2020.07.20.210534 — Posted: 2020-07-20
Probing the dynamic structure-function and structure-free energy relationships of the corona virus main protease with Biodynamics theory
Wan, H., Aravamuthan, V., Pearlstein, R. A.
10.1101/2020.07.19.211185 — Posted: 2020-07-20
De novo design of modular and tunable allosteric biosensors
Quijano-Rubio, A., Yeh, H.-W., Park, J., Lee, H., Langan, R. A., Boyken, S. E., Lajoie, M. J., Cao, L., Chow, C. M., Miranda, M. C., Wi, J., Hong, H. J., Stewart, L., Oh, B.-H., Baker, D.
10.1101/2020.07.18.206946 — Posted: 2020-07-20 Discussion: Onsite
CETSA MS profiling for a comparative assessment of FDA approved antivirals repurposed for COVID-19 therapy identifies Trip13 as a Remdesivir off-target
Friman, T., Chernobrovkin, A., Martinez Molina, D., Arnold, L. H.
10.1101/2020.07.19.210492 — Posted: 2020-07-20
Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication
Silvas, J. A., Jureka, A. S., Nicolini, A. M., Chvatal, S. A., Basler, C. F.
10.1101/2020.07.18.210211 — Posted: 2020-07-20
Haplotype Explorer: an infection cluster visualization tool for spatiotemporal dissection of the COVID-19 pandemic
Kawano-Sugaya, T., Yatsu, K., Sekizuka, T., Itokawa, K., Hashino, M., Tanaka, R., Kuroda, M.
10.1101/2020.07.19.179101 — Posted: 2020-07-20
The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models
Stegmann, K. M., Dickmanns, A., Gerber, S., Nikolova, V., Klemke, L., Manzini, V., Schloesser, D., Bierwirth, C., Freund, J., Sitte, M., Lugert, R., Salinas, G., Goerlich, D., Wollnik, B., Gross, U., Dobbelstein, M.
10.1101/2020.07.18.210013 — Posted: 2020-07-20
Cryo-electron Microscopy and Exploratory Antisense Targeting of the 28-kDa Frameshift Stimulation Element from the SARS-CoV-2 RNA Genome
Zhang, K., Zheludev, I. N., Hagey, R. J., Wu, M. T.-P., Haslecker, R., Hou, Y. J., Kretsch, R., Pintilie, G. D., Rangan, R., Kladwang, W., Li, S., Pham, E. A., Bernardin, C., Baric, R. S., Sheahan, T. P., Dsouza, V., Glenn, J. S., Chiu, W., Das, R.
10.1101/2020.07.18.209270 — Posted: 2020-07-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).